A Black Box warning on suicidal ideation and behavior, a REM program and a Medication Guide may hold back the sales growth of Valeant’s new psoriasis therapy in the US, Siliq, following its Feb. 15 approval, although the drug has been associated with high levels of total skin clearance, a finding that could differentiate it from competing products.
At last, some good news for hard-pressed Valeant Pharmaceuticals International Inc., with the US FDA announcing the approval of the psoriasis therapy, Siliq (brodalumab), on Feb. 15. The Canada-based multinational said it would start marketing Siliq in the US in the second half of 2017.
Brodalumab was approved in the US for the treatment of adults with moderate-to-severe plaque psoriasis, in patients who are candidates...
Fresh from having sold Anthos to Novartis, the new CEO is expected to update the oncology and dermatology-focused firm's strategy.
Green light follows a recent rejection by the US FDA to partner Regeneron's request for an extension to the dosing interval.
Recent moves in the industry include C-suite changes at Atalanta Therapeutics and Climb Bio, plus seven companies get new CMOs.
